Shares of Cogent Biosciences were higher after the company disclosed what it called positive top-line results from a recent trial of its treatment for certain types of mastocytosis, a rare disorder in ...

This study reveals the step-wise establishment of nuclear speckle-associated domains (SPADs) during mouse embryogenesis.

Cogent reported positive SUMMIT trial data for bezuclastinib in NonAdvSM and plans to file for FDA approval by late 2025.

Cogent Biosciences, Inc. is a Strong Buy after trial data for bezuclastinib & market growth potential in systemic ...

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase ...

Upadacitinib 15 mg — but not 7.5 mg — alongside a glucocorticoid taper demonstrated superior efficacy to placebo with a ...

Cogent Biosciences Inc. is eyeing an NDA submission to the U.S. FDA by the end of this year in the wake of positive top-line ...

A recent phase 2 clinical trial reveals that Ambroxol, a common cough medicine, shows promise in stabilizing psychiatric ...

Cogent's bezuclastinib showed strong efficacy in a non-advanced SM trial, with a planned FDA submission expected by the end ...

Bone cancer is a serious ailment. It involves abnormal cell growth in bones. It damages healthy tissues. It often affects the ...

Luspatercept-aamt shows significant survival benefits and transfusion independence in lower-risk MDS, reshaping treatment ...

A very special look was presented earlier this week by fashion designer Iris van Herpen at the Paris Haute Couture Week. The ...